Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

被引：53

作者：

Ogwang, Caroline ^{[1
]}

Afolabi, Muhammed ^{[2
]}

Kimani, Domtila ^{[1
]}

Jagne, Ya Jankey ^{[2
]}

Sheehy, Susanne H. ^{[3
]}

Bliss, Carly M. ^{[4
]}

Duncan, Christopher J. A. ^{[3
]}

Collins, Katharine A. ^{[4
]}

Knight, Miguel A. Garcia ^{[1
]}

Kimani, Eva ^{[1
]}

Anagnostou, Nicholas A. ^{[3
]}

Berrie, Eleanor ^{[5
]}

Moyle, Sarah ^{[5
]}

Gilbert, Sarah C. ^{[4
]}

Spencer, Alexandra J. ^{[4
]}

Soipei, Peninah ^{[1
]}

Mueller, Jenny ^{[2
]}

Okebe, Joseph ^{[2
]}

Colloca, Stefano ^{[6
]}

Cortese, Riccardo ^{[6
]}

Viebig, Nicola K. ^{[8
]}

Roberts, Rachel ^{[3
]}

Gantlett, Katherine ^{[3
]}

Lawrie, Alison M. ^{[3
]}

Nicosia, Alfredo ^{[6
,7
,9
]}

Imoukhuede, Egeruan B. ^{[8
]}

Bejon, Philip ^{[1
]}

Urban, Britta C. ^{[1
,10
]}

Flanagan, Katie L. ^{[2
]}

Ewer, Katie J. ^{[4
]}

Chilengi, Roma ^{[1
]}

Hill, Adrian V. S. ^{[3
,4
]}

Bojang, Kalifa ^{[2
]}

机构：

[1] Ctr Geog Med Res Coast, Kenya Med Res Inst, Kilifi, Kenya

[2] MRC Unit, Fajara, Gambia

[3] Churchill Hosp, Jenner Inst, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England

[4] Univ Oxford, Jenner Inst Labs, Oxford, England

[5] Univ Oxford, Churchill Hosp, Clin Biomfg Facil, Oxford, England

[6] Okairos AG, Rome, Italy

[7] CEINGE, Naples, Italy

[8] European Vaccine Initiat, Heidelberg, Germany

[9] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy

[10] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England

来源：

PLOS ONE | 2013年 / 8卷 / 03期

基金：

英国惠康基金; 英国医学研究理事会;

关键词：

VIRUS ANKARA VACCINES; FOWLPOX STRAIN FP9; T-CELLS RECOGNIZE; CIRCUMSPOROZOITE PROTEIN; IMMUNE-RESPONSES; RANDOMIZED-TRIAL; VIRAL VECTORS; RECOMBINANT; ADENOVIRUS; CHILDREN;

D O I：

10.1371/journal.pone.0057726

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naive adults following controlled human malaria infection (CHMI). Methodology: We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns. Results: ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC). Conclusions: ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.

引用

页数：11

共 27 条

[1] A phase I study to assess safety and immunogenicity of novel schedules for vaccination with candidate malaria vaccines ChAd63 ME-TRAP and MVA ME-TRAP
Bliss, C. M.
Ewer, K.
Anagnostou, N.
Havelock, T.
Poulton, I.
Lawrie, A.
Choudhary, P.
Hill, A.
[J]. IMMUNOLOGY, 2011, 135 : 77 - 77
[2] Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
Victorine Mensah
Danny Wright
Katie Ewer
Nick Edwards
Magatte Ndiaye
Phillip Bejon
Nicola Viebig
Babacar Faye
Adrian Hill
Badara Cisse
[J]. Malaria Journal, 13 (Suppl 1)
[3] Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
Mensah, Victorine A.
Gueye, Aly
Ndiaye, Magatte
Edwards, Nick J.
Wright, Danny
Anagnostou, Nicholas A.
Syll, Massamba
Ndaw, Amy
Abiola, Annie
Bliss, Carly
Gomis, Jules-Francois
Petersen, Ines
Ogwang, Caroline
Dieye, Tandakha
Viebig, Nicola K.
Lawrie, Alison M.
Roberts, Rachel
Nicosia, Alfredo
Faye, Babacar
Gaye, Oumar
Leroy, Odile
Imoukhuede, Egeruan B.
Ewer, Katie J.
Bejon, Philip
Hill, Adrian V. S.
Cisse, Badara
[J]. PLOS ONE, 2016, 11 (12):
[4] Safety and immunogenicity of heterologous prime-boost vaccine strategy with Adch63 ME-TRAP and MVA ME-TRAP in healthy adults and children in The Gambia
Afolabi, M.
[J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2012, 17 : 43 - 44
[5] Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations
Kimani, Domtila
Jagne, Ya Jankey
Cox, Momodou
Kimani, Eva
Bliss, Carly M.
Gitau, Evelyn
Ogwang, Caroline
Afolabi, Muhannmed O.
Bowyer, Georgina
Collins, Katharine A.
Edwards, Nick
Hodgson, Susanne H.
Duncan, Christopher J. A.
Spencer, Alexandra J.
Knight, Miguel G.
Drammeh, Abdoulie
Anagnostou, Nicholas A.
Berrie, Eleanor
Moyle, Sarah
Gilbert, Sarah C.
Soipei, Peninah
Okebe, Joseph
Colloca, Stefano
Cortese, Riccardo
Viebig, Nicola K.
Roberts, Rachel
Lawrie, Alison M.
Nicosia, Alfredo
Imoukhuede, Egeruan B.
Bejon, Philip
Chilengi, Roma
Bojang, Kalifa
Flanagan, Katie L.
Hill, Adrian V. S.
Urban, Britta C.
Ewer, Katie J.
[J]. MOLECULAR THERAPY, 2014, 22 (11) : 1992 - 2003
[6] Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
Afolabi, Muhammed O.
Tiono, Alfred B.
Adetifa, Uche J.
Yaro, Jean Baptiste
Drammeh, Abdoulie
Nebie, Issa
Bliss, Carly
Hodgson, Susanne H.
Anagnostou, Nicholas A.
Sanou, Guillaume S.
Jagne, Ya Jankey
Ouedraogo, Oumarou
Tamara, Casimir
Ouedraogo, Nicolas
Ouedraogo, Mirielle
Njie-Jobe, Jainaba
Diarra, Amidou
Duncan, Christopher J. A.
Cortese, Riccardo
Nicosia, Alfredo
Roberts, Rachel
Viebig, Nicola K.
Leroy, Odile
Lawrie, Alison M.
Flanagan, Katie L.
Kampman, Beate
Bejon, Philip
Imoukhuede, Egeruan B.
Ewer, Katie J.
Hill, Adrian V. S.
Bojang, Kalifa
Sirima, Sodiomon B.
[J]. MOLECULAR THERAPY, 2016, 24 (08) : 1470 - 1477
[7] HETEROLOGOUS PRIME-BOOST VACCINATION WITH CANDIDATE MALARIA VACCINES CHAD63-MVA ME-TRAP IS SAFE AND HIGHLY IMMUNOGENIC FOR EFFECTOR T-CELL INDUCTION WHEN CO-ADMINISTERED WITH EPI VACCINES IN HEALTHY GAMBIAN INFANTS AND NEONATES
Afolabi, Muhammed O.
Mensah, Victorine
Kanteh, Ebrima
Ndaw, Amy
Roetynck, Sophie
Clarke, Ed
Faye, Babacar
Imoukhuede, Egeruan B.
Lawrie, Alison
Roberts, Rachel
Jagne, Ya Jankey
Leroy, Odile
Viebig, Nicola
D'Alessio, Flavia
Kampmann, Beate
Ewer, Katie
Hill, Adrian V.
Cisse, Badara
Bojang, Kalifa
[J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (04): : 110 - 110
[8] IMMUNOGENICITY OF CHAD63/ MVA ME-TRAP MALARIA VECTORED VACCINE IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMIZED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES
Roetynck, Sophie
Mensah, Victorine
Kanteh, Ebrima
Bowyer, Georgina
Ndaw, Amy
Oko, Francis
Bliss, Carly
Cortese, Riccardo
Nicosia, Alfredo
Roberts, Rachel
D'Alessio, Flavia
Leroy, Odile
Faye, Babacar
Kampmann, Beate
Cisse, Badara
Bojang, Kalifa
Gerry, Stephen
Viebig, Nicola
Lawrie, Alison
Clarke, Ed
Imoukhuede, Egeruan
Ewer, Katie
Hill, Adrian
Afolabi, Muhammed
[J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 193 - 193
[9] Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
Georgina Bowyer
Muhammed O Afolabi
Carly M Bliss
Alfred B Tiono
Abdoulie Drammeh
Issa Nébié
Ya Jankey Jagne
Jean Baptiste Yaro
Egeruan B Imoukhuede
Katie L Flanagan
Beate Kampman
Nicola Viebig
Sodiomon B Sirima
Kalifa Bojang
Adrian VS Hill
Katie J Ewer
[J]. Malaria Journal, 13 (Suppl 1)
[10] A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
Bejon, Philip
Mwacharo, Jedidah
Kai, Oscar
Mwangi, Tabitha
Milligan, Paul
Todryk, Stephen
Keating, Sheila
Lang, Trudie
Lowe, Brett
Gikonyo, Caroline
Molyneux, Catherine
Fegan, Greg
Gilbert, Sarah C.
Peshu, Norbert
Marsh, Kevin
Hill, Adrian V. S.
[J]. PLOS CLINICAL TRIALS, 2006, 1 (06):

← 1 2 3 →